Newron Pharmaceuticals SpA (NWRN) - Net Assets

Latest as of June 2025: CHF1.58 Million CHF ≈ $2.00 Million USD

Based on the latest financial reports, Newron Pharmaceuticals SpA (NWRN) has net assets worth CHF1.58 Million CHF (≈ $2.00 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF61.39 Million ≈ $77.62 Million USD) and total liabilities (CHF59.81 Million ≈ $75.62 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NWRN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CHF1.58 Million
% of Total Assets 2.58%
Annual Growth Rate -12.13%
5-Year Change -91.55%
10-Year Change -96.07%
Growth Volatility 174.4

Newron Pharmaceuticals SpA - Net Assets Trend (2005–2024)

This chart illustrates how Newron Pharmaceuticals SpA's net assets have evolved over time, based on quarterly financial data. Also explore NWRN asset base for the complete picture of this company's asset base.

Annual Net Assets for Newron Pharmaceuticals SpA (2005–2024)

The table below shows the annual net assets of Newron Pharmaceuticals SpA from 2005 to 2024. For live valuation and market cap data, see market value of Newron Pharmaceuticals SpA.

Year Net Assets Change
2024-12-31 CHF1.46 Million
≈ $1.84 Million		 +104.87%
2023-12-31 CHF-29.91 Million
≈ $-37.81 Million		 -113.17%
2022-12-31 CHF-14.03 Million
≈ $-17.74 Million		 -551.56%
2021-12-31 CHF3.11 Million
≈ $3.93 Million		 -81.98%
2020-12-31 CHF17.25 Million
≈ $21.80 Million		 -53.13%
2019-12-31 CHF36.80 Million
≈ $46.52 Million		 -32.89%
2018-12-31 CHF54.84 Million
≈ $69.33 Million		 -19.03%
2017-12-31 CHF67.72 Million
≈ $85.62 Million		 +36.13%
2016-12-31 CHF49.75 Million
≈ $62.89 Million		 +34.05%
2015-12-31 CHF37.11 Million
≈ $46.92 Million		 +26.83%
2014-12-31 CHF29.26 Million
≈ $36.99 Million		 +38.74%
2013-12-31 CHF21.09 Million
≈ $26.66 Million		 -23.61%
2012-12-31 CHF27.61 Million
≈ $34.90 Million		 +319.26%
2011-12-31 CHF6.58 Million
≈ $8.33 Million		 -45.98%
2010-12-31 CHF12.19 Million
≈ $15.41 Million		 -58.37%
2009-12-31 CHF29.28 Million
≈ $37.02 Million		 -36.08%
2008-12-31 CHF45.81 Million
≈ $57.92 Million		 -20.19%
2007-12-31 CHF57.40 Million
≈ $72.57 Million		 -15.41%
2006-12-31 CHF67.86 Million
≈ $85.79 Million		 +298.70%
2005-12-31 CHF17.02 Million
≈ $21.52 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Newron Pharmaceuticals SpA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 2616100000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CHF10.69 Million 732.85%
Common Stock CHF3.99 Million 273.80%
Total Equity CHF1.46 Million 100.00%

Newron Pharmaceuticals SpA Competitors by Market Cap

The table below lists competitors of Newron Pharmaceuticals SpA ranked by their market capitalization.

Company Market Cap
Elitegroup Computer Systems Co Ltd
TW:2331
 $360.88 Million
Tourism Finance Corporation of India Limited
NSE:TFCILTD
 $361.00 Million
Southern States Bancshares Inc
NASDAQ:SSBK
 $361.07 Million
Barings Corporate Investors
NYSE:MCI
 $361.13 Million
Guiyang Xintian Pharmaceutical Co Ltd
SHE:002873
 $360.77 Million
Fleetpartners Group Ltd
AU:FPR
 $360.63 Million
Tupy S.A
SA:TUPY3
 $360.59 Million
Volcon Inc
NASDAQ:VLCN
 $360.58 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Newron Pharmaceuticals SpA's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from -29,908,000 to 1,458,000, a change of 31,366,000.
  • Net income of 15,843,000 contributed positively to equity growth.
  • Share repurchases of 15,414,000 reduced equity.
  • New share issuances of 15,414,000 increased equity.
  • Other comprehensive income increased equity by 12,081,000.
  • Other factors increased equity by 3,442,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CHF15.84 Million +1086.63%
Share Repurchases CHF15.41 Million -1057.2%
Share Issuances CHF15.41 Million +1057.2%
Other Comprehensive Income CHF12.08 Million +828.6%
Other Changes CHF3.44 Million +236.08%
Total Change CHF- %

Book Value vs Market Value Analysis

This analysis compares Newron Pharmaceuticals SpA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 182.07x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 2.37x to 182.07x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-12-31 CHF6.03 CHF14.30 x
2006-12-31 CHF17.90 CHF14.30 x
2007-12-31 CHF9.84 CHF14.30 x
2008-12-31 CHF7.68 CHF14.30 x
2009-12-31 CHF4.81 CHF14.30 x
2010-12-31 CHF1.84 CHF14.30 x
2011-12-31 CHF0.91 CHF14.30 x
2012-12-31 CHF3.38 CHF14.30 x
2013-12-31 CHF1.83 CHF14.30 x
2014-12-31 CHF2.31 CHF14.30 x
2015-12-31 CHF2.70 CHF14.30 x
2016-12-31 CHF3.39 CHF14.30 x
2017-12-31 CHF4.15 CHF14.30 x
2018-12-31 CHF3.07 CHF14.30 x
2019-12-31 CHF2.06 CHF14.30 x
2020-12-31 CHF0.97 CHF14.30 x
2021-12-31 CHF0.17 CHF14.30 x
2022-12-31 CHF-0.79 CHF14.30 x
2023-12-31 CHF-1.68 CHF14.30 x
2024-12-31 CHF0.08 CHF14.30 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Newron Pharmaceuticals SpA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 1086.63%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 30.83%
  • • Asset Turnover: 0.80x
  • • Equity Multiplier: 43.83x
  • Recent ROE (1086.63%) is above the historical average (-14.36%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 -87.66% 0.00% 0.00x 1.38x CHF-16.62 Million
2006 -24.17% -1377.08% 0.01x 1.27x CHF-23.19 Million
2007 -19.32% -275.57% 0.06x 1.23x CHF-16.83 Million
2008 -35.72% -416.07% 0.06x 1.32x CHF-20.95 Million
2009 -80.19% -923.72% 0.06x 1.42x CHF-26.41 Million
2010 -168.53% -2549.01% 0.04x 1.57x CHF-21.76 Million
2011 -97.87% -2301.79% 0.02x 2.06x CHF-7.10 Million
2012 -8.60% -26.61% 0.20x 1.62x CHF-5.14 Million
2013 -33.66% -200.57% 0.11x 1.50x CHF-9.21 Million
2014 -34.50% -648.36% 0.04x 1.27x CHF-13.02 Million
2015 -61.48% -958.66% 0.05x 1.20x CHF-26.53 Million
2016 -30.63% -226.54% 0.12x 1.14x CHF-20.21 Million
2017 -7.80% -39.34% 0.18x 1.08x CHF-12.05 Million
2018 -27.42% -373.54% 0.07x 1.09x CHF-20.52 Million
2019 -54.91% -287.11% 0.12x 1.64x CHF-23.89 Million
2020 -121.76% -399.35% 0.10x 2.97x CHF-22.72 Million
2021 -479.59% -258.61% 0.11x 16.25x CHF-15.21 Million
2022 0.00% -287.05% 0.16x 0.00x CHF-16.09 Million
2023 0.00% -179.13% 0.35x 0.00x CHF-13.23 Million
2024 1086.63% 30.83% 0.80x 43.83x CHF15.70 Million

Industry Comparison

This section compares Newron Pharmaceuticals SpA's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $152,573,779
  • Average return on equity (ROE) among peers: -30.07%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Newron Pharmaceuticals SpA (NWRN) CHF1.58 Million -87.66% 37.81x $360.88 Million
Addex Therapeutics Ltd (ADXN) $33.84 Million -92.04% 0.29x $7.10 Million
BB Biotech AG (BION) $1.91 Billion 10.59% 0.00x $2.25 Billion
Basilea Pharmaceutica AG (BSLN) $125.38 Million -47.04% 0.20x $699.48 Million
Evolva Holding SA (EVE) $21.86 Million -39.62% 1.03x $7.08 Million
Idorsia Ltd (IDIA) $-1.21 Billion 0.00% 0.00x $759.27 Million
Molecular Partners AG (MOLN) $135.79 Million -13.71% 0.36x $145.86 Million
Relief Therapeutics Holding AG (RLF) $14.30 Million -52.18% 0.39x $36.33 Million
Santhera Pharmaceuticals Holding AG (SANN) $104.47 Million -42.74% 0.08x $244.59 Million
Xlife Sciences AG (XLS) $235.23 Million 6.08% 1.08x $122.27 Million

About Newron Pharmaceuticals SpA

SW:NWRN Switzerland Biotechnology
Market Cap
$360.88 Million
CHF285.44 Million CHF
Market Cap Rank
#14173 Global
#149 in Switzerland
Share Price
CHF14.30
Change (1 day)
-3.38%
52-Week Range
CHF6.66 - CHF30.40
All Time High
CHF30.40
Categories
Companies in Switzerland Biotechnology
About

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more